Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies
The process of drug development involves non-clinical and clinical studies. Non-clinical studies are conducted using different protocols including animal studies, which mostly follow the Good Laboratory Practice (GLP) regulations. During the early pre-clinical development process, also known as Go/N...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Associação Brasileira de Divulgação Científica
|
| Series: | Brazilian Journal of Medical and Biological Research |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016001200301&lng=en&tlng=en |
| _version_ | 1811288141109133312 |
|---|---|
| author | E.L. Andrade A.F. Bento J. Cavalli S.K. Oliveira R.C. Schwanke J.M. Siqueira C.S. Freitas R. Marcon J.B. Calixto |
| author_facet | E.L. Andrade A.F. Bento J. Cavalli S.K. Oliveira R.C. Schwanke J.M. Siqueira C.S. Freitas R. Marcon J.B. Calixto |
| author_sort | E.L. Andrade |
| collection | DOAJ |
| description | The process of drug development involves non-clinical and clinical studies. Non-clinical studies are conducted using different protocols including animal studies, which mostly follow the Good Laboratory Practice (GLP) regulations. During the early pre-clinical development process, also known as Go/No-Go decision, a drug candidate needs to pass through several steps, such as determination of drug availability (studies on pharmacokinetics), absorption, distribution, metabolism and elimination (ADME) and preliminary studies that aim to investigate the candidate safety including genotoxicity, mutagenicity, safety pharmacology and general toxicology. These preliminary studies generally do not need to comply with GLP regulations. These studies aim at investigating the drug safety to obtain the first information about its tolerability in different systems that are relevant for further decisions. There are, however, other studies that should be performed according to GLP standards and are mandatory for the safe exposure to humans, such as repeated dose toxicity, genotoxicity and safety pharmacology. These studies must be conducted before the Investigational New Drug (IND) application. The package of non-clinical studies should cover all information needed for the safe transposition of drugs from animals to humans, generally based on the non-observed adverse effect level (NOAEL) obtained from general toxicity studies. After IND approval, other GLP experiments for the evaluation of chronic toxicity, reproductive and developmental toxicity, carcinogenicity and genotoxicity, are carried out during the clinical phase of development. However, the necessity of performing such studies depends on the new drug clinical application purpose. |
| first_indexed | 2024-04-13T03:30:55Z |
| format | Article |
| id | doaj.art-c597dbfb5d2d458ea47b010426ee9b04 |
| institution | Directory Open Access Journal |
| issn | 1414-431X |
| language | English |
| last_indexed | 2024-04-13T03:30:55Z |
| publisher | Associação Brasileira de Divulgação Científica |
| record_format | Article |
| series | Brazilian Journal of Medical and Biological Research |
| spelling | doaj.art-c597dbfb5d2d458ea47b010426ee9b042022-12-22T03:04:28ZengAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research1414-431X491210.1590/1414-431x20165646S0100-879X2016001200301Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studiesE.L. AndradeA.F. BentoJ. CavalliS.K. OliveiraR.C. SchwankeJ.M. SiqueiraC.S. FreitasR. MarconJ.B. CalixtoThe process of drug development involves non-clinical and clinical studies. Non-clinical studies are conducted using different protocols including animal studies, which mostly follow the Good Laboratory Practice (GLP) regulations. During the early pre-clinical development process, also known as Go/No-Go decision, a drug candidate needs to pass through several steps, such as determination of drug availability (studies on pharmacokinetics), absorption, distribution, metabolism and elimination (ADME) and preliminary studies that aim to investigate the candidate safety including genotoxicity, mutagenicity, safety pharmacology and general toxicology. These preliminary studies generally do not need to comply with GLP regulations. These studies aim at investigating the drug safety to obtain the first information about its tolerability in different systems that are relevant for further decisions. There are, however, other studies that should be performed according to GLP standards and are mandatory for the safe exposure to humans, such as repeated dose toxicity, genotoxicity and safety pharmacology. These studies must be conducted before the Investigational New Drug (IND) application. The package of non-clinical studies should cover all information needed for the safe transposition of drugs from animals to humans, generally based on the non-observed adverse effect level (NOAEL) obtained from general toxicity studies. After IND approval, other GLP experiments for the evaluation of chronic toxicity, reproductive and developmental toxicity, carcinogenicity and genotoxicity, are carried out during the clinical phase of development. However, the necessity of performing such studies depends on the new drug clinical application purpose.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016001200301&lng=en&tlng=enNon-clinical studiesGLP studiesSafetyPharmacokineticsToxicology |
| spellingShingle | E.L. Andrade A.F. Bento J. Cavalli S.K. Oliveira R.C. Schwanke J.M. Siqueira C.S. Freitas R. Marcon J.B. Calixto Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies Brazilian Journal of Medical and Biological Research Non-clinical studies GLP studies Safety Pharmacokinetics Toxicology |
| title | Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies |
| title_full | Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies |
| title_fullStr | Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies |
| title_full_unstemmed | Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies |
| title_short | Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies |
| title_sort | non clinical studies in the process of new drug development part ii good laboratory practice metabolism pharmacokinetics safety and dose translation to clinical studies |
| topic | Non-clinical studies GLP studies Safety Pharmacokinetics Toxicology |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016001200301&lng=en&tlng=en |
| work_keys_str_mv | AT elandrade nonclinicalstudiesintheprocessofnewdrugdevelopmentpartiigoodlaboratorypracticemetabolismpharmacokineticssafetyanddosetranslationtoclinicalstudies AT afbento nonclinicalstudiesintheprocessofnewdrugdevelopmentpartiigoodlaboratorypracticemetabolismpharmacokineticssafetyanddosetranslationtoclinicalstudies AT jcavalli nonclinicalstudiesintheprocessofnewdrugdevelopmentpartiigoodlaboratorypracticemetabolismpharmacokineticssafetyanddosetranslationtoclinicalstudies AT skoliveira nonclinicalstudiesintheprocessofnewdrugdevelopmentpartiigoodlaboratorypracticemetabolismpharmacokineticssafetyanddosetranslationtoclinicalstudies AT rcschwanke nonclinicalstudiesintheprocessofnewdrugdevelopmentpartiigoodlaboratorypracticemetabolismpharmacokineticssafetyanddosetranslationtoclinicalstudies AT jmsiqueira nonclinicalstudiesintheprocessofnewdrugdevelopmentpartiigoodlaboratorypracticemetabolismpharmacokineticssafetyanddosetranslationtoclinicalstudies AT csfreitas nonclinicalstudiesintheprocessofnewdrugdevelopmentpartiigoodlaboratorypracticemetabolismpharmacokineticssafetyanddosetranslationtoclinicalstudies AT rmarcon nonclinicalstudiesintheprocessofnewdrugdevelopmentpartiigoodlaboratorypracticemetabolismpharmacokineticssafetyanddosetranslationtoclinicalstudies AT jbcalixto nonclinicalstudiesintheprocessofnewdrugdevelopmentpartiigoodlaboratorypracticemetabolismpharmacokineticssafetyanddosetranslationtoclinicalstudies |